

BioAsia 2026 focuses on Global TechBio for Future of Life Sciences

17 February 2026 | News

Companies from France, Indonesia, US announce significant investments in Telangana



The 23rd edition of BioAsia 2026 officially commenced on 17 Feb in Hyderabad. Organised by the Government of Telangana, BioAsia has established itself over two decades as a global platform fostering collaboration, driving investment, and accelerating advancements across the entire life sciences value chain.

Under the theme 'TechBio Unleashed: AI, Automation, and the Biology Revolution,' BioAsia 2026 underscores the integration of biology with artificial intelligence, automation, and data sciences.

Bio Asia 2026 began with the inauguration of the International Exhibition and a formal opening ceremony led by Chief Minister A. Revanth Reddy, with senior leaders reaffirming Telangana's leadership in life sciences and TechBio healthcare. At the ceremony, Prof. Bruce L. Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, Perelman School of Medicine at the University of Pennsylvania was presented with the Genome Valley Excellence Award for his pioneering work in Cancer therapies.

At Bio Asia 2026, major announcements were made by Opella Healthcare (France), Vaksindo Animal Health (division of JAPFA, Indonesia), Tredence Inc (US), and Rx Propellant. The Swiss Pharmaceutical giant, Novartis unveiled a logo celebrating 25 years of its GCC presence in India with Hyderabad as its largest centre globally outside its headquarters in Basel, Switzerland.

On the sidelines of the conference, the Chief Minister met the leadership teams from Miltenyi Biotec, Sanofi, MSD, Takeda along with the Consul General of Indonesia and team from Vaksindo, Indonesia. The IT Minister besides the meetings with the Chief Minister, met with the leaders from NIBRT, Google DeepMind besides other engagements.

The plenary address by Pushmeet Kohli, VP of Science, Google DeepMind, UK focused on role of AI in bio medical discovery and drug development.

Sessions focused on scaling innovation from lab to bedside, driving growth amid global challenges, and advancing biologics

from discovery to clinical proof and CMC readiness. The discussions also revolved around the next gen CRDMO's where AI would act as a force multiplier across the value chain.

The day concluded with the CEO Conclave, a discussion where Pharma Industry Leaders opined on the future of pharma and biotech through 2030, highlighting the growth, innovation, technology advancements, geopolitics and resilience shaping the competitiveness across the industry.

A. Revanth Reddy, Chief Minister of Telangana, said, "Telangana has established itself as a global leader in life sciences, pharmaceuticals, and healthcare. The Next Gen Life Sciences Policy 2026-30 emphasizes that future growth will be driven by cross-border collaboration, international capital, and shared innovation. This reflects the state's dedication to innovation and excellence. Telangana is developing a future-ready ecosystem that transforms scientific breakthroughs into practical healthcare solutions for India and the global community. This strategy aims to foster sustainable economic growth and reinforce the state's leadership in the global life sciences sector."

D. Sridhar Babu, Minister for IT, Electronics and Communications, and Industries and Commerce, Government of Telangana, said, "The state's new life sciences policy emphasizes frontier science and advanced manufacturing, including cell and gene therapies, peptides, and precision fermentation. It aims to bolster the ecosystem in clinical research, pharma services, diagnostics, medical electronics, and digital health, positioning Telangana as a global destination for life sciences investment. Telangana is preparing its workforce, industry and institutions to lead in the next wave of life sciences and healthcare innovation."

Sanjay Kumar, IAS, Special Chief Secretary, Industries and Commerce and ITE and C Departments, Government of Telangana, said, "The Telangana Life Sciences team is facilitating partnerships, supporting advanced manufacturing and ensuring that emerging technologies are effectively translated into real-world healthcare solutions. This edition of BioAsia provides a platform to identify opportunities, address challenges and create actionable pathways for research, development and investment. By combining foresight, structured policy and robust support systems. This reinforces Telangana's position as a trusted global partner in the rapidly evolving TechBio landscape."

Shakthi M. Nagappan, CEO, Telangana Life Sciences, said, "As the life sciences sector rapidly evolves, BioAsia 2026 marks a pivotal moment where artificial intelligence, automation, and data sciences intersect with biology to transform healthcare and biotech. Telangana's commitment to fostering innovation and translational research ensures scientific insights translate into practical solutions. These initiatives boost economic growth, enhance patient outcomes, and position Hyderabad as key players in the dynamic TechBio industry."

Investments announced at Bio Asia 2026

Opella Healthcare, a global consumer healthcare company, spun off from Sanofi, with its global headquarters in France, and is expanding its GCC operations in a 42,000 sq. ft. facility, creating up to 500 jobs within the next year.

Vaksindo Animal Health, a division of JAPFA Indonesia, is establishing a state-of-the-art BSL-3 vaccine manufacturing facility in Genome Valley. The facility will focus on producing vaccines for poultry, cattle, swine, and aquaculture.

Tredence Inc, an AI and data science company, is announcing its Hyderabad operations as a dedicated innovation hub focused on AI-driven healthcare and life sciences analytics. The facility will span approximately 18,000 sq. ft. and support its global operations.

Rx Propellant (RxP) will develop a new, large-format life sciences campus in Genome Valley, Hyderabad as part of its long-term commitment to strengthening India's life sciences ecosystem. The project will comprise over 1 million square feet of advanced laboratory infrastructure spread across ~12 acres of site delivered in phases over the next six years.